These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20232400)

  • 1. Photodermatosis associated with eculizumab (Soliris): a novel monoclonal antibody directed against the complement protein C5.
    Balagula Y; Newman SB; Lacouture ME
    Am J Hematol; 2010 May; 85(5):392-3. PubMed ID: 20232400
    [No Abstract]   [Full Text] [Related]  

  • 2. Life-threatening desquamating rash and hyperammonemia following administration of eculizumab for paroxysmal nocturnal hemoglobinuria.
    Knoll BM; Letendre L; Steensma DP
    Am J Hematol; 2008 Nov; 83(11):881-3. PubMed ID: 18756538
    [No Abstract]   [Full Text] [Related]  

  • 3. Eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
    Hill A
    Clin Adv Hematol Oncol; 2005 Nov; 3(11):849-50. PubMed ID: 16491626
    [No Abstract]   [Full Text] [Related]  

  • 4. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
    Rother RP; Rollins SA; Mojcik CF; Brodsky RA; Bell L
    Nat Biotechnol; 2007 Nov; 25(11):1256-64. PubMed ID: 17989688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria.
    Keating GM; Lyseng-Williamson KA; McKeage K
    BioDrugs; 2012 Apr; 26(2):125-30. PubMed ID: 22350448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs that inhibit complement.
    Schrezenmeier H; Höchsmann B
    Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Young NS; Schubert J; Brodsky RA; Socié G; Muus P; Röth A; Szer J; Elebute MO; Nakamura R; Browne P; Risitano AM; Hill A; Schrezenmeier H; Fu CL; Maciejewski J; Rollins SA; Mojcik CF; Rother RP; Luzzatto L
    N Engl J Med; 2006 Sep; 355(12):1233-43. PubMed ID: 16990386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [C5: eculizumab].
    Miyamoto K
    Brain Nerve; 2014 Oct; 66(10):1191-9. PubMed ID: 25296873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
    Dmytrijuk A; Robie-Suh K; Cohen MH; Rieves D; Weiss K; Pazdur R
    Oncologist; 2008 Sep; 13(9):993-1000. PubMed ID: 18784156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Eculizumab in paroxysmal nocturnal hemoglobinuria].
    Socié G; Varoqueaux N; Peffault de Latour R
    Med Sci (Paris); 2009 Dec; 25(12):1126-9. PubMed ID: 20035691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eculizumab (Soliris) for paroxysmal nocturnal hemoglobinuria.
    Med Lett Drugs Ther; 2007 Sep; 49(1270):79-80. PubMed ID: 17878890
    [No Abstract]   [Full Text] [Related]  

  • 12. Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria.
    Hill A; Rother RP; Hillmen P
    Haematologica; 2005 Dec; 90(12 Suppl):ECR40. PubMed ID: 16464755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Elebute M; Kelly R; Urbano-Ispizua A; Hill A; Rother RP; Khursigara G; Fu CL; Omine M; Browne P; Rosse W
    Am J Hematol; 2010 Aug; 85(8):553-9. PubMed ID: 20658586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [With paroxysmal nocturnal haemoglobinuria and treatment with eculizumab].
    Algado JT; Luque R; Nuñez R; Sanchez B
    Enferm Infecc Microbiol Clin; 2012 Feb; 30(2):109-10. PubMed ID: 22197277
    [No Abstract]   [Full Text] [Related]  

  • 15. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn.
    Hallstensen RF; Bergseth G; Foss S; Jæger S; Gedde-Dahl T; Holt J; Christiansen D; Lau C; Brekke OL; Armstrong E; Stefanovic V; Andersen JT; Sandlie I; Mollnes TE
    Immunobiology; 2015 Apr; 220(4):452-9. PubMed ID: 25468724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan).
    Schols S; Nunn MA; Mackie I; Weston-Davies W; Nishimura JI; Kanakura Y; Blijlevens N; Muus P; Langemeijer S
    Br J Haematol; 2020 Jan; 188(2):334-337. PubMed ID: 31840801
    [No Abstract]   [Full Text] [Related]  

  • 17. Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Muus P; Szer J; Hill A; Höchsmann B; Kulasekararaj A; Risitano AM; Van Den Neste E; Liljeholm M; Ebrahim KS; Bedrosian CL; Gao X; Ames D; Socié G
    Am J Hematol; 2016 Mar; 91(3):E16-7. PubMed ID: 26690023
    [No Abstract]   [Full Text] [Related]  

  • 18. Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria.
    Kelly RJ; Höchsmann B; Szer J; Kulasekararaj A; de Guibert S; Röth A; Weitz IC; Armstrong E; Risitano AM; Patriquin CJ; Terriou L; Muus P; Hill A; Turner MP; Schrezenmeier H; Peffault de Latour R
    N Engl J Med; 2015 Sep; 373(11):1032-9. PubMed ID: 26352814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria.
    Schrezenmeier H; Höchsmann B
    Expert Rev Hematol; 2009 Feb; 2(1):7-16. PubMed ID: 21082989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study.
    Loschi M; Porcher R; Barraco F; Terriou L; Mohty M; de Guibert S; Mahe B; Lemal R; Dumas PY; Etienne G; Jardin F; Royer B; Bordessoule D; Rohrlich PS; Fornecker LM; Salanoubat C; Maury S; Cahn JY; Vincent L; Sene T; Rigaudeau S; Nguyen S; Lepretre AC; Mary JY; Corront B; Socie G; Peffault de Latour R
    Am J Hematol; 2016 Jun; 91(4):366-70. PubMed ID: 26689746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.